Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.

Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.
复制标题

DOI:
10.1016/j.canep.2021.102090
复制
发表时间:
2022-03
影响因子:
2.6
通讯作者:
Poynter JN
Poynter JN
中科院分区:
医学3区
文献类型:
--
作者:
Linabery AM;Roesler MA;Richardson M;Warlick ED;Nguyen PL;Cioc AM;Poynter JN

文献摘要

参考文献

被引文献

相似文献

Autoimmune diseases and hematopoietic malignancies are known to cluster within individuals, suggesting intertwined etiologies. A limited number of studies have evaluated pre-existing medical conditions as risk factors for myelodysplastic syndromes (MDS). We evaluated associations between autoimmune disease and other medical conditions and risk of MDS. Cases were identified through the Minnesota Cancer Reporting System. Controls were identified through the Minnesota State driver’s license/identification card list. History of autoimmune disease and other medical conditions was based on self-report; proxy interviews were not conducted. Unconditional logistic regression was used to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CI). We included 395 cases and 694 controls. Cases were significantly more likely to report a diagnosis of any autoimmune disease when compared with controls (aOR=1.41, 95% CI: 1.05–1.89) after adjustment for age, sex, education, NSAID use, exposure to benzene and body mass index. When we evaluated specific autoimmune conditions, a statistically significant association was observed for hypothyroidism (aOR=2.16, 95% CI: 1.39–3.34) and odds ratios were elevated for inflammatory bowel disease (aOR=1.75) and systemic lupus erythematosus (SLE; aOR=3.65), although these associations did not reach statistical significance. Presence of an autoimmune condition did not impact overall survival (p=0.91). Our results validate previous findings of an association between autoimmune disease and MDS. Further studies are required to determine whether this association is due to shared etiology, treatment for autoimmune diseases, or altered immune surveillance or bone marrow damage caused by the autoimmune condition.
DOI: 10.1200/jco.2011.34.8540
发表时间: 2011-07-20
影响因子: 45.3
作者:
Kristinsson, Sigurdur Y.;Bjorkholm, Magnus;Goldin, Lynn R.
通讯作者: Goldin, Lynn R.
DOI: 10.1002/cncr.22570
发表时间: 2007-04-15
期刊: CANCER
影响因子: 6.2
作者:
Ma, Xiaomei;Does, Monique;Mayne, Susan T.
通讯作者: Mayne, Susan T.
DOI: 10.1056/nejmoa021933
发表时间: 2003-10-16
影响因子: 158.5
作者:
Arbuckle, MR;McClain, MT;Harley, JB
通讯作者: Harley, JB
DOI: 10.1093/aje/kwp074
发表时间: 2009-06-15
影响因子: 5
作者:
Ma, Xiaomei;Lim, Unhee;Schatzkin, Arthur
通讯作者: Schatzkin, Arthur
DOI: 10.1007/s00277-018-3302-0
发表时间: 2018-08-01
影响因子: 3.5
作者:
Montoro, Julia;Gallur, Laura;Valcarcel, David
通讯作者: Valcarcel, David